Retropharyngeal Abscess Market Research Report- Forecast till 2030

Retropharyngeal Abscess Market Research Report: information by diagnosis (X-rays and computed tomography, blood tests, physical exam, others), by treatment (antibiotics, pain killers, surgical drainage, others), and by end-user-forecast till 2030

ID: MRFR/Pharma/3491-HCR | 110 Pages | Published By Rahul Gotadki on April 2023         

Retropharyngeal abscess Market Scenario 

The retropharyngeal abscess market is expected to reach USD 5,963 Million by 2030, and the market is projected to grow at a CAGR of ~ 4.4% during the forecast period 2022-2030. A retropharyngeal abscess is a serious infection, usually starts in the lymph nodes, characterised by collection of pus at the back of the throat. Retropharyngeal abscess typically occurs in children under the age of eight, sometimes it can also affect adults. The symptoms of retropharyngeal abscess include difficulty or noisy breathing, difficulty and pain while swallowing, drooling, severe cough, severe throat pain, neck stiffness or swelling, muscle spasms in the neck among others. Retropharyngeal abscess is generally preceded by upper respiratory infections mostly a middle ear or sinus infection.

The causes of retropharyngeal abscess are trauma or injury, medical procedure, dental procedures, alcohol intake, diabetes, cancer, AIDS, weakened immune system or a chronic diseases such as tuberculosis and others. Other complications indicated are pneumonia, blood clots in the jugular vein, mediastinitis, osteomyelitis and others. If left untreated, retropharyngeal abscess infection can spread to other parts of the body resulting in septic shock and organ failure. In severe instances, a retropharyngeal abscess can lead to death. The most common bacteria involved are Streptococcus, Staphylococcus, and others. Other infections, such as HIV and tuberculosis can also cause the retropharyngeal abscess. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications. Retropharyngeal abscess also slightly more common in males than females.

The market drivers for global retropharyngeal abscess market, are rise in demand due to the growing younger and susceptible population, increasing screening, urgency of the retropharyngeal abscess treatment, and rise in risk factors. The rise in cases of retropharyngeal abscess due to increase in Methicillin-resistant Staphylococcus aureus (MRSA) infections also stimulates the market. The market restraints are complications such as risk of bleeding, infections, pain, especially during surgery, high cost of retropharyngeal abscess treatment, lack of cardiac care infrastructure, and lack of focus on other diseases by the developing regions and others.


The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.

Based on the diagnosis, the market of retropharyngeal abscess has been segmented as X-rays and computed tomography, blood tests, physical exam and others.

Based on the treatment, the market for retropharyngeal abscess has been segmented as calcium antibiotics, pain killers, surgical drainage and others.

Based on the market end user, the retropharyngeal abscess has been segmented as hospitals and clinics, research and academics and others.

Regional Analysis 

A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the market of retropharyngeal abscess. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster market development of retropharyngeal abscess in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.

Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.

Asia Pacific market of retropharyngeal abscess is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region. However the low expenditure on healthcare coupled with the poor incomes in the developing regions is a dent on the market.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.

Key Players in the Global Retropharyngeal abscess Market 

Some of the key players profiled in the report are Merck KGaA, Johnson & Johnson, AstraZeneca plc, Sanofi S.A., Pfizer, Mylan N.V, Novartis AG, Teva pharmaceutical company, GlaxoSmithKline plc., and others.

Intended Audience

  • Global Retropharyngeal abscess manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities 

Report Scope:

Report Attribute/Metric Details
  Market Size   2022-2030: USD 5,963 Million
  CAGR   2022-2030: 4.4%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, treatment, and end user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Merck KGaA, Johnson & Johnson, AstraZeneca plc, Sanofi S.A., Pfizer, Mylan N.V, Novartis AG, Teva pharmaceutical company, GlaxoSmithKline plc., and others
  Key Market Opportunities   Development of broad spectrum antibiotics
  Key Market Drivers

  • Rise in demand due to the growing younger and susceptible population
  • increasing screening, urgency of the retropharyngeal abscess treatment

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Retropharyngeal Abscess Market valuation would be USD 5,963 Million by 2030.

    Retropharyngeal Abscess Market CAGR would be 4.4% during the forecast period.

    End users mentioned in the Retropharyngeal Abscess Market report are hospitals & clinics, & academics, and others

    Germany would lead the Retropharyngeal Abscess Market.

    The Retropharyngeal Abscess Market players are Johnson & Johnson, Merck KGaA, Sanofi S.A., Pfizer, AstraZeneca plc, Novartis AG, Mylan N.V, GlaxoSmithKline plc., Teva pharmaceutical company, and others.